<DOC>
	<DOCNO>NCT01570309</DOCNO>
	<brief_summary>Vitamin D ( Vit D ) status emerge risk marker great interest cardiovascular disease ( CVD ) . Lower serum level Vit D associate cardiac risk factor prevalent cardiovascular disease . Vit D insufficiency remain prevalent free living population United States especially urban , multi-ethnic low income Northern cities.To date , prospective randomize trial use Vit D supplementation modify CVD risk evaluate outcome perform . The investigator propose double-blind , randomize wait-list control trial subject Coronary Artery Disease ( CAD ) Vit D deficiency two specific aim . Specific aim 1 measure endothelial function use reactive hyperemia peripheral arterial tonometry ( RH-PAT ) treatment Vit D replacement therapy . Specific Aim 2 measure level inflammation treatment Vit D replacement therapy . These aim test hypothesis Vit D repletion improve endothelial function reduce level detectable inflammation plasma subject .</brief_summary>
	<brief_title>Vitamin D Repletion Coronary Artery Disease</brief_title>
	<detailed_description>100 subject angiographically document CAD Vit D deficiency randomize 50,000 IU oral ergocalciferol ( active treatment group ) placebo ( delay intervention group ) week 12 week . The investigator measure endothelial function randomization week 12 use RH-PAT serologically measure adhesion molecule ( s-VCAM , s-ICAM , soluble e-selectin ) . Changes level plasma cytokine chemokines represent T-cell activation pathway ( IL-12 , IFN-g CXCL-10 - `` IFN-g axis '' ) investigator link coronary atherogenesis ( independent CRP ) poor CV outcome , measure 12 week study period . Given publish evidence show Vit D influence T- cell pathway , specific aim 2 add mechanistic insight proposal . High sensitivity C-reactive protein ( hs-CRP ) measure well establish traditional marker inflammation CAD also link Vit D status .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Vitamin D Deficiency</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>Male nonpregnant female great 18 year age â‰¥ 50 % angiographic stenosis least 1 coronary artery document previous revascularization Serum 25hydroxyvitamin D &lt; 20 ng/ml confinement nursing facility , institution home GFR &lt; 60 ml/min ( MDRD equation ) presence liver disease hypercalcemia NYHA class III IV heart failure cardiogenic shock time presentation current plan emergent CABG prior gastric small bowel surgery pancreatitis malabsorption inflammatory bowel disease autoimmune disease active malignancy current use &gt; 800 IU/day vitamin D Current use dilantin , phenobarbitol , immunosuppressant , immunostimulant therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>vitamin D ,</keyword>
	<keyword>vitamin D deficiency</keyword>
	<keyword>coronary artery disease</keyword>
	<keyword>ergocalciferol</keyword>
	<keyword>endothelial function</keyword>
	<keyword>adhesion molecule</keyword>
	<keyword>inflammation</keyword>
	<keyword>IL-12</keyword>
	<keyword>interferon-gamma</keyword>
	<keyword>CXCL-10</keyword>
	<keyword>reactive hyperemia peripheral arterial tonometry</keyword>
	<keyword>endothelial dysfunction</keyword>
	<keyword>cytokine</keyword>
	<keyword>chemokines</keyword>
</DOC>